Satellos Bioscience (NASDAQ:MSLE) Price Target Raised to $11.00

Satellos Bioscience (NASDAQ:MSLE) had its target price raised by HC Wainwright from $1.20 to $11.00 in a research report report published on Monday morning,Benzinga reports. HC Wainwright currently has a buy rating on the stock. HC Wainwright also issued estimates for Satellos Bioscience’s Q2 2026 earnings at ($0.36) EPS, Q3 2026 earnings at ($0.37) EPS, Q4 2026 earnings at ($0.37) EPS, FY2026 earnings at ($1.45) EPS, Q1 2027 earnings at ($0.40) EPS, Q2 2027 earnings at ($0.43) EPS, Q3 2027 earnings at ($0.46) EPS, Q4 2027 earnings at ($0.50) EPS, FY2027 earnings at ($1.78) EPS, FY2028 earnings at ($1.89) EPS, FY2029 earnings at ($1.21) EPS and FY2030 earnings at $0.34 EPS.

Other analysts also recently issued research reports about the company. Zacks Research raised Satellos Bioscience to a “hold” rating in a research note on Tuesday, February 10th. Cantor Fitzgerald initiated coverage on Satellos Bioscience in a research report on Wednesday, March 11th. They set an “overweight” rating for the company. Wall Street Zen lowered Satellos Bioscience to a “strong sell” rating in a research report on Saturday, March 14th. Finally, Weiss Ratings started coverage on Satellos Bioscience in a research note on Wednesday, February 11th. They issued a “sell (d-)” rating on the stock. Two investment analysts have rated the stock with a Buy rating, one has issued a Hold rating and one has issued a Sell rating to the stock. Based on data from MarketBeat.com, Satellos Bioscience has an average rating of “Hold” and an average target price of $11.00.

Satellos Bioscience Stock Up 7.3%

Satellos Bioscience stock opened at $6.04 on Monday. Satellos Bioscience has a twelve month low of $4.53 and a twelve month high of $13.39. The company has a market capitalization of $93.38 million, a PE ratio of -3.90 and a beta of 1.37.

Satellos Bioscience (NASDAQ:MSLE) last issued its quarterly earnings data on Friday, March 27th. The company reported ($0.47) EPS for the quarter, missing analysts’ consensus estimates of ($0.36) by ($0.11).

Trending Headlines about Satellos Bioscience

Here are the key news stories impacting Satellos Bioscience this week:

• Positive Sentiment: HC Wainwright raised several near‑term EPS estimates (Q2 & Q3 2026, Q4 2026, Q2 & Q3 2027) and boosted FY2026/FY2027 outlooks, reflecting smaller expected losses in the nearer quarters — a potential positive catalyst for sentiment and valuation.
• Positive Sentiment: The analyst maintained a “Buy” rating and an $11.00 price target, signaling continued analyst conviction in upside from current levels and supporting investor interest.
• Neutral Sentiment: HC Wainwright published a long‑range FY2030 estimate (EPS $0.34) that implies a substantial turnaround, but this is distant and speculative; treat as a long‑term scenario rather than near‑term proof. Article Title
• Negative Sentiment: There are also downward revisions: Q1 2027 was cut (to a larger expected loss) and HC Wainwright trimmed FY2028 and FY2029 EPS (wider losses than previously modeled). These longer‑dated negative revisions increase uncertainty around the sustainability of the recovery.
• Negative Sentiment: Satellos reported an EPS miss in its most recent quarter (reported loss larger than consensus), a likely driver of some of the model adjustments and a reminder of execution risk going forward.

About Satellos Bioscience

Satellos Bioscience Inc is a regenerative medicine company dedicated to developing novel therapeutics which stimulate or restore muscle regeneration in severe disorders. The company’s lead program is focused on developing an oral therapeutic drug for Duchenne muscular dystrophy. Satellos Bioscience Inc, formerly known as iCo Therapeutics Inc, is based in Toronto, Ontario.